FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Improving Outcomes Assessment in Chronic GVHD

Active, not recruiting

Conditions: Chronic Graft Versus Host Disease

First Posted Date: 2008-03-18

Last Posted Date: 2025-03-19

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 601

Registration Number: NCT00637689

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 6 locations

Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis

Phase 1

Completed

Conditions: Systemic Scleroderma
Severe Systemic Sclerosis

Interventions: Drug: fludarabine phosphate
Drug: Mycophenolic Acid
Drug: tacrolimus
Radiation: total-body irradiation
Procedure: bone marrow transplantation
Procedure: reduced intensity allogeneic hematopoietic stem cell transplantation
Procedure: quality-of-life assessment
Other: laboratory biomarker analysis
Other: flow cytometry
Procedure: biopsy

First Posted Date: 2008-02-25

Last Posted Date: 2018-06-04

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 3

Registration Number: NCT00622895

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States

Carbohydrates and Related Biomarkers

Not Applicable

Completed

Conditions: Healthy
Overweight

Interventions: Other: Low Glycemic Load Diet
Other: High Glycemic Load Diet

First Posted Date: 2008-02-25

Last Posted Date: 2012-01-05

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 89

Registration Number: NCT00622661

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma

Phase 1

Completed

Conditions: Recurrent Grade 1 Follicular Lymphoma
Recurrent Small Lymphocytic Lymphoma
Refractory Chronic Lymphocytic Leukemia
Splenic Marginal Zone Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Marginal Zone Lymphoma
Waldenström Macroglobulinemia
B-cell Chronic Lymphocytic Leukemia
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Recurrent Mantle Cell Lymphoma

Interventions: Biological: therapeutic autologous lymphocytes
Drug: cyclophosphamide
Biological: aldesleukin
Genetic: polymerase chain reaction
Genetic: gene rearrangement analysis
Procedure: lymph node biopsy
Biological: genetically engineered lymphocyte therapy
Procedure: bone marrow aspiration
Other: flow cytometry
Other: laboratory biomarker analysis
Other: enzyme-linked immunosorbent assay

First Posted Date: 2008-02-22

Last Posted Date: 2014-08-06

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 12

Registration Number: NCT00621452

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant

Phase 2

Completed

Conditions: Refractory Multiple Myeloma
Stage I Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma

Interventions: Drug: lenalidomide

First Posted Date: 2008-02-21

Last Posted Date: 2017-05-18

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 18

Registration Number: NCT00619684

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Adult Acute Myeloid Leukemia in Remission
CD45-Positive Neoplastic Cells Present
Refractory Anemia With Ring Sideroblasts
Chronic Myelomonocytic Leukemia
Refractory Anemia With Excess Blasts
Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
Adult Acute Lymphoblastic Leukemia in Remission
Previously Treated Myelodysplastic Syndrome
Refractory Cytopenia With Multilineage Dysplasia

Interventions: Procedure: Allogeneic Bone Marrow Transplantation
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Radiation: Iodine I 131 Monoclonal Antibody BC8
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Drug: Tacrolimus
Radiation: Total-Body Irradiation

First Posted Date: 2008-01-09

Last Posted Date: 2023-02-09

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 26

Registration Number: NCT00589316

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Phase 1

Terminated

Conditions: Graft Versus Host Disease
Leukemia
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases

Interventions: Biological: alemtuzumab
Drug: busulfan
Drug: cyclophosphamide
Drug: methotrexate
Drug: tacrolimus
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2007-11-07

Last Posted Date: 2017-05-24

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 1

Registration Number: NCT00555048

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders

Phase 2

Completed

Conditions: Non-Cancer Diagnosis
Immunodeficiency Syndrome

Interventions: Biological: Alemtuzumab
Procedure: Allogeneic Bone Marrow Transplantation
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclosporine
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Radiation: Total-Body Irradiation

First Posted Date: 2007-11-04

Last Posted Date: 2020-02-17

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 29

Registration Number: NCT00553098

Locations: 🇺🇸
Children's Hospital and Research Center at Oakland, Oakland, California, United States
🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States

and more 3 locations

Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma

Phase 1

Completed

Conditions: Stage IV Melanoma
Recurrent Melanoma

Interventions: Biological: therapeutic autologous lymphocytes
Biological: aldesleukin
Drug: cyclophosphamide
Procedure: biopsy
Other: immunohistochemistry staining method
Other: flow cytometry
Genetic: polymerase chain reaction

First Posted Date: 2007-11-04

Last Posted Date: 2017-02-15

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 10

Registration Number: NCT00553306

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Sonographic Visibility of Breast Biopsy Marker Clips Up to 4 Weeks After Placement

Completed

Conditions: Breast Cancer

First Posted Date: 2007-10-24

Last Posted Date: 2008-12-31

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 25

Registration Number: NCT00548392

Locations: 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States

Home Terms & Conditions Privacy Policy